Pharmaceutical industry – Page 40
-
BusinessUS poised to approve its first ‘biosimilar’ drug
FDA panel recommends Sandoz’s copy of Amgen’s Neupogen
-
-
Business
EU recommends Parkinson’s drug for approval
First new molecule for a decade, but Alzheimer’s still posing challenges as antibody treatment withdrawn from trials
-
BusinessMerck & Co to buy antibiotics specialist Cubist
Pharma giant remains committed to $9.5bn deal despite key Cubist patents being invalidated by court ruling
-
BusinessSolving iron’s solubility problem
Technology profile: MRC Human Nutrition Research - anaemia supplements with fewer side effects
-
Business
Big pharma opens up abandoned drugs
Seven firms will make 68 stalled compounds available for academic research
-
Business
Otsuka to buy neurology specialist Avanir
$3.5bn deal adds to Otsuka’s mental health portfolio and strengthens its US presence
-
BusinessCystic Fibrosis Foundation sells drug royalty rights for $3.3bn
‘Venture philanthropy’ model pays off with massive cash injection for charity
-
OpinionProgress at the pace of the slowest
Chemistry is rarely the rate-limiting process in getting a drug to market, says Derek Lowe
-
Business
UCB sells speciality generics subsidiary
Firm will use $1.5bn proceeds to reduce debt and concentrate on developing new drugs in neurology and immunology
-
BusinessActavis rescues Allergan with $66 billion deal
Deal ends takeover fight with Valeant – but Actavis must still be ‘fairly ruthless’ to justify the high price
-
Business
Ranbaxy sues over withdrawn US approvals
Company says decision is ‘unconstitutional’ and deprives it of hundreds of millions of dollars in revenue
-
Business
Labcorp to buy Covance and enter contract research
Firm wants to diversify away from diagnostics, but law firm investigation suggests investors are unconvinced of the deal’s value
-
Business
Perrigo to buy Omega Pharma for €3.6bn
Deal strengthens Perrigo’s over-the-counter portfolio and pushes strongly into Europe
-
Business
Chinese buyer resurrects US Boehringer plant
UniTao will take over manufacturing site scheduled for closure, saving over 200 jobs
-
Business
Judge slashes fines in drug safety case
Takeda and Eli Lilly’s $9 billion damages in diabetes trial reduced to $38 million
-
BusinessCHF3bn redevelopment for Roche’s Basel site
New buildings will move employees out of rented office space
-
Business
Amgen stacks up additional job cuts
Up to 1100 more staff face redundancy in ongoing restructuring plan
-
Business
Amgen seeks injunction to protect patents
Sanofi and Regeneron sued over cholesterol-regulating antibodies
-
BusinessIndian manufacturers hit back over quality claims
Study showing drugs exported to Africa are substandard prompts backlash from generic drugmakers